Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN): $28.40

0.95 (+3.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SUPN POWR Grades


  • SUPN scores best on the Value dimension, with a Value rank ahead of 96.8% of US stocks.
  • The strongest trend for SUPN is in Value, which has been heading down over the past 179 days.
  • SUPN's current lowest rank is in the Growth metric (where it is better than 6.57% of US stocks).

SUPN Stock Summary

  • Supernus Pharmaceuticals Inc's stock had its IPO on May 1, 2012, making it an older stock than 35.81% of US equities in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Supernus Pharmaceuticals Inc is reporting a growth rate of -36.07%; that's higher than 29.79% of US stocks.
  • The volatility of Supernus Pharmaceuticals Inc's share price is greater than that of 30.12% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Supernus Pharmaceuticals Inc, a group of peers worth examining would be VIVO, RMTI, QGEN, BKYI, and KVHI.
  • SUPN's SEC filings can be seen here. And to visit Supernus Pharmaceuticals Inc's official web site, go to www.supernus.com.

SUPN Valuation Summary

  • SUPN's price/sales ratio is 2.6; this is 31.58% lower than that of the median Healthcare stock.
  • SUPN's price/sales ratio has moved down 164 over the prior 114 months.
  • Over the past 114 months, SUPN's price/earnings ratio has gone up 11.9.

Below are key valuation metrics over time for SUPN.

Stock Date P/S P/B P/E EV/EBIT
SUPN 2021-08-31 2.6 1.9 14.6 10.4
SUPN 2021-08-30 2.5 1.8 14.0 10.0
SUPN 2021-08-27 2.5 1.8 14.0 10.0
SUPN 2021-08-26 2.3 1.7 13.3 9.6
SUPN 2021-08-25 2.4 1.7 13.5 9.7
SUPN 2021-08-24 2.3 1.7 13.3 9.6

SUPN Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 58.49%.
  • Its 4 year revenue growth rate is now at 152.41%.
  • Its 4 year price growth rate is now at 44%.
Over the past 33 months, SUPN's revenue has gone up $155,385,000.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 564.282 110.297 81.75
2021-06-30 570.953 120.006 100.185
2021-03-31 556.353 165.683 111.126
2020-12-31 520.397 138.399 126.95
2020-09-30 477.286 150.257 129.311
2020-06-30 424.291 182.316 118.174

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SUPN has a Quality Grade of B, ranking ahead of 91.1% of graded US stocks.
  • SUPN's asset turnover comes in at 0.375 -- ranking 128th of 682 Pharmaceutical Products stocks.
  • RETA, INVA, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.375 0.860 0.164
2021-03-31 0.370 0.886 0.187
2020-12-31 0.366 0.899 0.196
2020-09-30 0.357 0.920 0.201
2020-06-30 0.343 0.949 0.173
2020-03-31 0.356 0.957 0.155

SUPN Price Target

For more insight on analysts targets of SUPN, see our SUPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.67 (Moderate Buy)

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $28.40 52-week high $34.50
Prev. close $27.45 52-week low $23.15
Day low $27.42 Volume 229,731
Day high $28.49 Avg. volume 455,393
50-day MA $29.64 Dividend yield N/A
200-day MA $29.52 Market Cap 1.52B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biop

Yahoo | February 22, 2022

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report preliminary fourth quarter and full year 2021 financial results and full year 2022 financial guidance after the market closes on Monday, February 28, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice

Yahoo | February 22, 2022

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. Food and Drug Administration (FDA) that the company’s New Drug Application (NDA) resubmission for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in P

Yahoo | February 22, 2022

Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?

Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | February 21, 2022

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo 0.82%
3-mo -8.30%
6-mo -7.22%
1-year -5.59%
3-year -11.44%
5-year -20.56%
YTD -2.61%
2021 15.90%
2020 6.07%
2019 -28.60%
2018 -16.64%
2017 57.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6438 seconds.